Leerink Partners Remains Bullish After Opdivo and HCV Help Drive 3Q Beat for Bristol-Myers Squibb (BMY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
Bristol-Myers Squibb Reports Third Quarter Financial Results
October 27, 2015 6:59 AM EDTIncreases Revenues 4% to $4.1 Billion Posts Third Quarter GAAP EPS of $0.42 and Non-GAAP EPS of $0.39 Achieves Significant U.S. Regulatory and Clinical Milestones in Immuno-Oncology Opdivo Approved for Previously-Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Regardless of PD-L1 Expression Opdivo-Yervoy Regimen Approved for Metastatic Melanoma Opdivo Granted Breakthrough Therapy Designation for Metastatic Renal Cell Carcinoma Refines 2015 GAAP EPS Guidance Range to $1.02 - $1.07... More
